Treatment of an HPV16-positive, HLA-A2, <i>PIK3CA</i> mutant cell line (CaSki) with T cells (NexImmune), specific to HPV16 tumor antigens inhibited in a T cell: target cell ratio-dependent manner. Here, PIK3CA is linked to neoplasm.